- ►diabetesjournals.org JS Rana, PS Monraats, AH Zwinderman, MPM de … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—To assess the role of metabolic syndrome in the development
of restenosis, we performed an analysis in a population of patients from the GENetic DEterminants
of Restenosis (GENDER) study. The GENDER project, a multicenter prospective study, ... Cited by 29 - Related articles - All 7 versions
CK Haddock, WSC Poston, JE Taylor, M Conard, … - American Heart …, 2003 - pt.wkhealth.com From the Mid America Heart Institute, St Luke's Hospital, and, University of Missouri, Kansas
City, Mo. ... Supported in part by unrestricted grants awarded by Pharmacia and the Agency
for Healthcare Research and Quality (AHRQ R01HS11282-01). ... Reprint requests: C. ... Cited by 13 - Related articles - BL Direct - All 7 versions
T Kasai, K Miyauchi, T Kurata, S Okazaki, K … - Hypertension …, 2008 - nature.com Metabolic syndrome (MS) is highly prevalent and an established key risk factor for coronary artery
disease, regardless of the presence or absence of diabetes mellitus (DM). Long-term follow-up
studies have addressed the influence of MS with and without DM on the prognosis of ... Cited by 3 - Related articles - BL Direct - All 4 versions
[CITATION] Estado atual do tratamento e controle do diabetes melito, da dislipidemia e da …
IM Benseñor, PA Lotufo, JD Mion, F Nobre - Mion Jr D, Nobre F. Risco cardiovascular …, 2002 Cited by 4 - Related articles
O Johansen, M Abdelnoor, M Brekke, I … - Scandinavian …, 2001 - informahealthcare.com Objective—The major concern about percutaneous transluminal coronary angioplasty
(PTCA) is the high incidence of restenosis. Methods—Demographic, clinical and biochemical
data were recorded 2 weeks prior to PTCA in 388 patients ful lling the criteria for initial ... Cited by 20 - Related articles - BL Direct - All 6 versions
T Katayama, H Ueba, K Tsuboi, N Kubo, T Yasu, M … - American Heart Journal, 2007 - Elsevier Twenty-eight nondiabetic patients with MS after bare-metal stent implantation were randomized
to 6-month treatment with or without 30 mg/d of pioglitazone (pioglitazone group [PIO] of 14 patients
with 16 lesions and control group [CONT] of 14 patients with 16 lesions). At baseline and ... Cited by 11 - Related articles - All 27 versions
CAO Zheng, Z Yu-jie, Z Ying-xin, LIU Yu-yang, GUO … - Chinese medical journal, 2006 - cmj.org Background Recent studies have shown that thiazolidinediones (TZDs) could reduce in-stent
restenosis and improve clinical outcomes in patients with type 2 diabetes after coronary stent
implantation. It remains unclear whether nondiabetic patients with metabolic syndrome ... Cited by 11 - Related articles - Cached - BL Direct - All 6 versions
JS Rana, MA Mittleman, KK Ho, DE Cutlip - American Heart Journal, 2005 - Elsevier We studied 6186 patients pooled from 6 major coronary stent clinical trials. Clinical restenosis
was defined as target lesion revascularization (TLR) at 1 year. Body mass index was classified
according to World Health Organization criteria as underweight (<18.5 kg/m 2 ), normal ... Cited by 11 - Related articles - All 23 versions
E Nikolsky, E Kosinski, GJ Mishkel, C Kimmelstiel, … - The American journal of …, 2005 - Elsevier The effect of obesity on repeat coronary revascularization and restenosis in patients who undergo
stent implantation has not been reported. We therefore examined the database from the multicenter
randomized TAXUS-IV trial to determine the effect of body mass index (BMI) on outcomes ... Cited by 14 - Related articles - All 8 versions
E Nikolsky, GW Stone, CL Grines, DA Cox, E Garcia, … - American Heart Journal, 2006 - Elsevier Baseline BMI was measured in 2035 (98%) randomized patients; 552 (27%) patients have normal
weight (BMI <25 kg/m 2 ), 915 (45%) were overweight (≥25 to <30 kg/m 2 ), and 568 (28%) were
obese (≥30 kg/m 2 ). Compared with normal-weight patients, obese patients were ... Cited by 14 - Related articles - All 22 versions
